Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-week, Randomised, Controlled, Open-label, Two-group Parallel, Multi-centre Trial Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin Both in a Basal Bolus Regimen With or Without Metformin in Chinese Inpatients With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment

NCT01486966 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01486966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01486966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-week, Randomised, Controlled, Open-label, Two-group Parallel, Multi-centre Trial Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin Both in a Basal Bolus Regimen With or Without Metformin in Chinese Inpatients With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Terminated
Start date
November 30, 2011
Completion date
June 30, 2012
Enrollment
58 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2